SREBF2 and neoplasm: The current study has successfully developed and validated a novel signature consisting of five PR-related lncRNAs (i.e., SREBF2-AS1 and HPN-AS1, both of which are engaged in the development of prognostic models for ferroptosis and tumour mutation burden among patients with HCC) (27, 28).